Feasibility of integration of modalities in melanomas and sarcomas.
Chemotherapy was administered in the immediate postoperative period to seventy patients (52 with melanomas and 18 with sarcomas) after a total of eighty-seven major operations, with no morbidity or mortality traceable to the chemotherapy. There was no apparent interference with wound healing or what would be considered a normal postoperative course. Fourteen of these patients (5 with melanomas and 9 with sarcomas) received a combination of radiation anc chemotherapy initiated in the postoperative period, and it was tolerated well. This combination appears to be safe, provided the field of radiation is not so large that is may add significantly to the myelosuppressive effect of chemotherapy and the dosage of concomitantly administered radiopotentiating agent(s) is reduced. Sixteen patients had Bacillus Calmette-Gúerin (BCG) immunotherapy in the immediate postoperative period without complications. This policy of a tight interweaving of modalities is safe, has the theoretic advantage of an earlier concerted attack on microscopic residual tumor, and appears particularly promising in sarcomas.
D001500:BCG Vaccine / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use; D006801:Humans; D008545:Melanoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008558:Melphalan / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012509:Sarcoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D012878:Skin Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine; D004961:Estramustine; D003606:Dacarbazine; D008558:Melphalan